The phrase "a proprietary methodology" is correct and usable in written English.
It can be used when referring to a specific method or approach that is owned and controlled by an individual or organization, often implying exclusivity or uniqueness.
Example: "Our company has developed a proprietary methodology that sets us apart from our competitors in the industry."
Alternatives: "an exclusive method" or "a unique approach".
The foremost limitations of the present study arise from methodological uncertainty in replicating a study based on a proprietary methodology.
San Francisco's StarMine has developed a proprietary methodology for predicting when a company is likely to report results that differ from the consensus estimate.
Since over 90% of CMOs agree that their organizations must develop a publishing function, this report also provides best practices and a proprietary methodology for enabling the enterprise publishing process with technology.
We also have three other funds that are based on a stock-selection model that captures and isolates which companies are most likely to grow their dividends in the future, a proprietary methodology we called DIVCON.
You can brand it as a proprietary methodology.
Human oligodendrocytes were generated by a proprietary methodology of Kadimastem (Weizmann Science Park, Nes-Ziona, Israel; www.kadimastem.com).
The differences in unsatisfactory rates due to LBC platform we report here are most likely a function of differences in the proprietary methodology for each platform.
Towards the end of the book comes the inevitable pitch: The authors recommend a "Conscious Business Audit," for which a footnote explains they have "developed our own proprietary methodology".
An innovative, proprietary methodology was developed to produce, by plasma spraying deposition, a ceramic composite containing SiC particles dispersed in a ZrB2 matrix.
Surgical scaffold materials are available from several companies and are unique products manufactured by proprietary methodology.
Using proprietary methodology, the high-affinity pyridine or imidazole metal-binding group found in current clinical CYP17 inhibitors was replaced with novel, less avid, metal-binding groups in concert with potency-enhancing molecular scaffold modifications.
